Toronto Dominion Bank Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Toronto Dominion Bank raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 124,308 shares of the medical equipment provider’s stock after purchasing an additional 9,076 shares during the period. Toronto Dominion Bank’s holdings in Hologic were worth $8,961,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of HOLX. Venturi Wealth Management LLC increased its stake in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Smithfield Trust Co raised its stake in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in shares of Hologic in the 4th quarter worth about $49,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.1%

Shares of NASDAQ HOLX opened at $56.47 on Wednesday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a market cap of $12.58 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 2.14 and a beta of 0.54. The business’s 50 day moving average price is $58.59 and its 200-day moving average price is $67.07. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the firm posted $1.03 earnings per share. The company’s revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Martin D. Madaus acquired 5,445 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research report on Friday, May 2nd. Raymond James reaffirmed an “outperform” rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Citigroup dropped their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.